Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.

被引：0
|
作者：
Mustafayev, Fatma Nihan Akkoc [1 ]
Munsell, Mark [1 ]
Gutierrez-Barrera, Angelica M. [1 ]
Yam, Clinton [1 ]
Layman, Rachel M. [1 ]
Arun, Banu [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10587
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
    Oliveira, Jennifer L.
    Greipp, Patricia T.
    Rangan, Aruna
    Jatoi, Aminah
    Nguyen, Phuong L.
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [22] Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
    Jennifer L. Oliveira
    Patricia T. Greipp
    Aruna Rangan
    Aminah Jatoi
    Phuong L. Nguyen
    Blood Cancer Journal, 12
  • [23] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Yvette Drew
    Jonathan Ledermann
    Geoff Hall
    Daniel Rea
    Ros Glasspool
    Martin Highley
    Gordon Jayson
    Julieann Sludden
    James Murray
    David Jamieson
    Sarah Halford
    Gary Acton
    Zoe Backholer
    Raffaella Mangano
    Alan Boddy
    Nicola Curtin
    Ruth Plummer
    British Journal of Cancer, 2016, 114 : 723 - 730
  • [24] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Drew, Yvette
    Ledermann, Jonathan
    Hall, Geoff
    Rea, Daniel
    Glasspool, Ros
    Highley, Martin
    Jayson, Gordon
    Sludden, Julieann
    Murray, James
    Jamieson, David
    Halford, Sarah
    Acton, Gary
    Backholer, Zoe
    Mangano, Raffaella
    Boddy, Alan
    Curtin, Nicola
    Plummer, Ruth
    BRITISH JOURNAL OF CANCER, 2016, 114 (07) : 723 - 730
  • [25] The Evolution of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer
    Domchek, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 330 - 332
  • [26] Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
    Sandhu, Shahneen K.
    Yap, Timothy A.
    de Bono, Johann S.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 9 - 20
  • [27] BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
    Okuma, Hitomi Sumiyoshi
    Yonemori, Kan
    TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 271 - 286
  • [28] BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
    Darabi, Sourat
    Braxton, David R. R.
    Xiu, Joanne
    Carneiro, Benedito A. A.
    Swensen, Jeff
    Antonarakis, Emmanuel S. S.
    Liu, Stephen V. V.
    McKay, Rana R. R.
    Spetzler, David
    El-Deiry, Wafik S. S.
    Demeure, Michael J. J.
    MEDICINA-LITHUANIA, 2022, 58 (12):
  • [29] Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Yvette Drew
    Jonathan Ledermann
    Geoff Hall
    Daniel Rea
    Ros Glasspool
    Martin Highley
    Gordon Jayson
    Julieann Sludden
    James Murray
    David Jamieson
    Sarah Halford
    Gary Acton
    Zoe Backholer
    Raffaella Mangano
    Alan Boddy
    Nicola Curtin
    Ruth Plummer
    British Journal of Cancer, 2016, 114 : e21 - e21
  • [30] Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
    Comen, Elizabeth A.
    Robson, Mark
    CANCER JOURNAL, 2010, 16 (01) : 48 - 52
12345